Arcutis publishes long-term ZORYVE safety data for pediatric atopic dermatitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pedi
March 10, 2026 9:00 AM EDTZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages 2-5 who achieved disease clearance and who switched to proactive twice-weekly application sustained disease control for a median duration of ~8 monthsThese results further support the Companys focus on expanding options for pediatric populations
WESTLAKE VILLAGE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a... More
